Cassava Sciences (SAVA) said Monday that its late-stage trial of simufilam in mild-to-moderate Alzheimer's disease did not meet the co-primary endpoints of cognitive and functional improvement.
Secondary and exploratory biomarker endpoints also were not met, the clinical-stage company said, adding that the drug maintained a favorable safety profile despite the trial outcomes.
Shares of the company were down 83% in recent premarket activity.
Price: 4.36, Change: -22.12, Percent Change: -83.5
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。